Entera Bio Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd. on June 27, 2023. The Company is an emerging growth company incorporated in Israel, with its ordinary shares (ENTX) and warrants (ENTXW) listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event regarding the Company's warrants.
Material Changes and Events
- Warrant Expiration: Warrants issued in connection with the July 2, 2018 IPO will expire at 5:00 p.m. Eastern Time on July 2, 2023.
- Trading Suspension: Trading of the Warrants (ENTXW) on Nasdaq will be suspended following the close of business on June 28, 2023.
- Delisting: Nasdaq intends to file a Form 25 to effect the delisting of the Warrants and their deregistration under Section 12(b) of the Exchange Act.
- Ordinary Shares Status: The listing and trading of the Company's Ordinary Shares (ENTX) will not be affected by the expiration and delisting of the Warrants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks beyond the procedural details of the warrant expiration. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Confirm the final trading date for Warrants (ENTXW) is June 28, 2023.
- Verify the expiration time of Warrants is 5:00 p.m. Eastern Time on July 2, 2023.
- Ensure Ordinary Shares (ENTX) continue to trade normally on Nasdaq.
- Check for any subsequent filings regarding the formal delisting of the Warrants via Form 25.